Additionally, the anti‐atherosclerosis action of LAV‐BPIFB4 gene therapy was attributed to a mechanism involving the stromal cell‐derived factor‐1 (SDF‐1) and related CXCR4 receptor.8 Here, BPIFB4 is linked to atherosclerosis.